Pure Global AI
NCT06313970Not yet recruiting

First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients

A Multicenter,Open-label,Exploratory Study of QL1706 Plus Nab-paclitaxel and Gemcitabine With or Without Bevacizumab as First-line Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
Fudan UniversityPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Pancreatic Cancer
Drug/Device/Intervention
QL1706
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Fudan University
Timeline & enrollment
Phase
Phase 2
Start date
Apr 15, 2024
End date
Apr 15, 2026
Enrollment
50 participants
Primary outcome

Objective response rate (ORR)

Summary

This is a multicenter, open-label, exploratory study to evaluate the efficacy and safety of
 QL1706 plus nab-paclitaxel and gemcitabine with or without bevacizumab as first-line
 treatment in patients with unresectable locally advanced or metastatic pancreatic cancer

ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06313970
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06313970 through Pure Global AI's free database. This Phase 2 trial is sponsored by Fudan University and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.